NuCana (ADR) (NCNA)
Develops ProTide oncology candidates that redesign nucleoside agents for cancer cells.
Something off on this page? Send us feedback.
Develops ProTide-based oncology candidates, adapting known nucleoside agents to improve delivery of active metabolites into cancer cells. It is a pre-commercial research-and-development business whose future revenue depends on approvals or licensing and collaboration transactions.
Develops ProTide oncology candidates designed to deliver pre-activated forms of nucleoside analogs into cancer cells, aiming to bypass transport, activation, resistance, and toxic-breakdown limitations associated with older agents. Its current pipeline centers on NUC-7738, a cordycepin-derived candidate being expanded in melanoma combinations, and NUC-3373, which seeks to deliver the active metabolite associated with 5-fluorouracil more directly in solid-tumor settings.
Operates from Edinburgh across US and international clinical and regulatory environments as a small internal drug-development organization. Research, clinical trials, manufacturing, testing, and supply rely materially on third parties rather than internal commercial infrastructure.
The business has no approved products or commercial revenue. Progress rests on clinical safety and efficacy, regulatory approval, manufacturing reliability, evolving standards of care, and patent and license rights involving Cardiff-related entities.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $26.2M · Total debt $901.1K · Total assets $34.6M · Shareholders' equity $27.2M
- Revenue
- $0
- Operating income
- −$4.7M
- Net income
- −$4.2M
Reported in GBP, converted at the latest exchange rate
No dividends on record.
| Insiders4 holders · as of Apr 1, 2026 | 0.69% | 41.9K ADS | |
| Otherremainder | 99.31% | 6.03M ADS |
6.07M ADS (1 ADS = 25 ordinary shares) as of Aug 21, 2026 · holders as of their latest filing
The share count is from the company's Dec 2024 annual report; nothing newer is on file here.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Hugh GriffithInsiderdirector, officer: Chief Executive Officer | 0.66% | 1.00M ordinary | Form 4filed Mar 18, 2026 ↗ |
Jeffrey D. BlossInsiderofficer: Chief Medical Officer | 0.03% | 47,136 ordinary | Form 4filed Mar 19, 2026 ↗ |
Martin C.B. MellishInsiderdirector | 0.00% | 28 ordinary | Form 4filed Mar 20, 2026 ↗ |
Elliott M. LevyInsiderdirector | 0.00% | 13 ordinary | Form 4filed Apr 1, 2026 ↗ |
Baillie Gifford & Co (Scottish partnership)Institution | —11.00% of class, as filed | — | 13D/Gfiled Jan 28, 2021 ↗ |
| See all 14 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Bristol-Myers Squibb
Established checkpoint regimens dominate advanced melanoma care.
- Iovance Biotherapeutics
Amtagvi is a direct post-PD-1 melanoma alternative.
- Replimune Group
RP1 plus nivolumab targets PD-1-failed melanoma.
- Takeda (ADR)
FRUZAQLA competes for previously treated metastatic colorectal cancer.
- Amgen
Vectibix competes in biomarker-selected metastatic colorectal cancer.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| NuCana (ADR) | $1.36 | −3.18% | $8.4M | — | — | — | — |
| Bristol-Myers Squibb | $67.50 | −0.23% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Iovance Biotherapeutics | $8.64 | +0.06% | $3.85B | — | — | 11.8 | +65.7% |
| Replimune Group | $15.92 | −0.38% | $1.34B | — | — | — | — |
| Takeda (ADR) | $18.53 | +0.47% | $58.65B | 51.2 | 56.7 | 2.0 | +5.8% |
| Amgen | $442.48 | −0.08% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Median | 27.5 | 18.9 | 4.5 | +7.7% |